666,666 Shares in Kyverna Therapeutics, Inc. $KYTX Acquired by Propel Bio Management LLC

Posted by George Bondi on Jun 7th, 2026

Propel Bio Management LLC bought a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund bought 666,666 shares of the company’s stock, valued at approximately $6,267,000. Kyverna Therapeutics accounts for approximately 5.4% of Propel Bio Management LLC’s investment portfolio, making the stock its 6th largest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in KYTX. AIGH Capital Management LLC bought a new stake in shares of Kyverna Therapeutics in the 4th quarter worth approximately $14,100,000. RFG Advisory LLC bought a new stake in shares of Kyverna Therapeutics in the 4th quarter worth approximately $4,185,000. Woodline Partners LP bought a new stake in shares of Kyverna Therapeutics in the 3rd quarter worth approximately $1,513,000. Simplify Asset Management Inc. bought a new stake in shares of Kyverna Therapeutics in the 4th quarter worth approximately $1,808,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Kyverna Therapeutics during the third quarter valued at approximately $886,000. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Stock Performance

Shares of KYTX opened at $7.47 on Friday. The company’s 50 day moving average price is $9.02 and its 200 day moving average price is $8.53. Kyverna Therapeutics, Inc. has a 52 week low of $2.52 and a 52 week high of $13.67. The company has a market capitalization of $454.10 million, a PE ratio of -2.28 and a beta of 1.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 8.15 and a current ratio of 8.15.

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. Research analysts expect that Kyverna Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on KYTX. Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Kyverna Therapeutics in a report on Wednesday. Finally, JPMorgan Chase & Co. cut their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Get Our Latest Report on Kyverna Therapeutics

Kyverna Therapeutics Company Profile

(Free Report)

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.